Insmed Inc INSM

NAS: INSM | ISIN: US4576693075   30/05/2025
69,73 USD (+0,75%)
(+0,75%)   30/05/2025

8 mei 2025 · Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update · Persbericht

29 april 2025 · Insmed To Present at the BofA Securities 2025 Health Care Conference · Persbericht

24 april 2025 · Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 · Persbericht

23 april 2025 · New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis · Persbericht

23 april 2025 · Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 · Persbericht

25 maart 2025 · Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference · Persbericht

10 maart 2025 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

6 september 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

8 augustus 2024 · Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update · Persbericht

2 augustus 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

29 juli 2024 · Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 · Persbericht

5 juli 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

3 juli 2024 · Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference · Persbericht

27 juni 2024 · Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 · Persbericht

7 juni 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

5 juni 2024 · Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

30 mei 2024 · Insmed to Host Commercial Webinar on June 4, 2024 · Persbericht

30 mei 2024 · Insmed Announces Pricing of $650 Million Public Offering of Common Stock · Persbericht

29 mei 2024 · Insmed Announces Proposed $500 Million Public Offering of Common Stock · Persbericht

28 mei 2024 · Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis · Persbericht

Mijn selecties